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Sotalol 
Objectives. This study determined the effect of sotalol on atrial 
function after electrical cardioversion ofatrial fibrillation. 
Background. After electrical cardioversion ofatrial fibrillation, 
the Doppler mitral A wave is often diminished, representing 
impaired atrial contractile function. Sotalol is an effective atrial 
antiarrhythmic drug with class III and beta-adrenergic blocking 
properties. Although the negative inotropic effect of sotalol on the 
ventricle is minimal in patients with normal ventricular function, 
it may manifest negative inotropy when ventricular function is 
impaired. We postulated that after cardioversion, when intrinsic 
atrial function is impaired, sotalol may have an adverse ffect on 
the atrium. 
Methods. Thirty-seven patients enrolled in a randomized, 
double-blind study of sotalol for maintenance of sinus rhythm 
were studied by quantitative Doppler echocardiography within 
24 h of electrical cardioversion a d, for those still in sinus rhythm, 
again at 1 month. Doppler variables (E and A wave velocities and 
integrals) in patients receiving sotalol were compared with those 
in patients receiving placebo. 
Results. After electrical cardioversion, peak A wave velocity and 
A wave time-velocity integral in the 20 patients receiving placebo 
were reduced compared with normal values. In the 17 patients 
receiving sotalol (median dose 320 mg twice daily) these variables 
were further educed (mean [-+SD] peak A wave velocity 19.4 - 
5.5 vs. 38.4 -+ 14.7 cm/s, p < 0.001 and mean A wave time-velocity 
integral 1.7 -+ 0.6 vs. 3.4 -+ 1.4 cm, p < 0.001, in sotalol- vs. 
placebo-treated patients, respectively). Early diastolic filling (E 
wave variables) did not differ between sotalol- and placebo-treated 
groups. At 1 month, five sotalol- and six placebo-treated patients 
remained in sinus rhythm, and A wave variables had increased for 
the whole group, with a greater increase in sotalol-treated pa- 
tients. 
Conclusions. After electrical cardioversion, when atrial stun- 
ning is prominent, sotalol has a negative atrial inotropic effect. 
This effect may be temporary, as suggested by resolution at 1 
month. Negative inotropic effects of antiarrhythmic drugs on the 
atrium should be considered in assessing Doppler variables of left 
ventricular filling. 
(J Am CoU Cardiol 1995;25:665-71) 
Sotalol is a class III antiarrhythmic agent with beta-adrenergic 
blocking properties (1). The most widely studied preparation 
of sotalol, and the formulation currently available in the 
United States, is a racemic mixture of dextro and levo isomers 
(2). The levo isomer is responsible for the beta-blocking aspect 
of the drug, but the dextro isomer appears to be virtually 
devoid of this property (3,4). Despite its beta-blocking prop- 
erties, sotalol has less of a negative inotropic effect on the 
myocardium than propranolol or other standard beta-blocking 
agents (5,6), probably because the sotalol-induced lengthening 
of the action potential duration in cardiac tissue delays the 
inactivation of the slow calcium channel, thus augmenting 
myocardial contractility (1,6,7). The hemodynamic response to 
sotalol in individual patients is dose dependent and is also 
related to the degree of baseline impairment of the underlying 
myocardium (8-10). Thus, although several studies have 
shown minimal effects on indexes of myocardial contractility 
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during short-term therapy in patients with clinically stable 
disease, longer term use has been associated with the devel- 
opment of clinical congestive heart failure in some patients 
with a reduced ejection fraction (11). 
Sotalol is an effective agent for the prevention of both atrial 
and ventricular arrhythmias (11-15). Although several studies 
have documented sotalol's efficacy in terminating or prevent- 
ing atrial fibrillation (12-15), its effect on atrial function is 
virtually unexplored. In isolated rat atria sotalol inhibits the 
positive inotropic response that is normally produced by 
suprathreshold electrical stimulation (6). To our knowledge, 
this negative inotropic effect in atrial tissue, which is almost 
entirely related to the levo isomer (16), has not been studied in 
either intact animals or humans, and indeed the influence of 
any cardioactive agent on atrial function is rarely considered. 
In the present study we examine this concept and report a 
negative inotropic effect of sotalol on the atrium immediately 
after electrical cardioversion of atrial fibrillation to sinus 
rhythm. 
Methods  
Patient selection. This Doppler echocardiographic study 
was performed in a subgroup of patients who were enrolled in 
a multicenter investigation of the ability of sotalol to maintain 
©1995 by the ?umerican College of Cardiolo D, 0735-1097/95/$9.50 
0735-1097(94)00452-V 
666 POLLAK AND FALK JACC Vol. 25, No. 3 
SOTALOL AND ATRIAL ARRHYTHMIA March 1, 1995:665-71 
sinus rhythm after cardioversion (Bristol-Myers Squibb Co., 
unpublished ata, on file). Patients were eligible for the 
antiarrhythmic study if they had had atrial fibrillation sustained 
for >2 weeks but <1 year. Subjects, all of whom were >18 
years old, were excluded from the study for any of the 
following: 1) concomitant therapy with other antiarrhythmic 
drugs or with beta-blockers, verapamil or diltiazem; 2) signif- 
icant conduction abnormalities; 3) recent myocardial infarc- 
tion or cardiac surgery; 4) uncompensated heart failure; 
5) unstable angina or active myocarditis; 6) uncontrolled 
hypertension; 7) clinically significant chronic obstructive lung 
disease; 8) insulin-dependent diabetes mellitus; 9) significant 
hepatic or renal dysfunction. 
Patients were allocated in a randomized, blinded fashion, to 
receive ither sotalol or placebo. The initial dose of sotalol was 
160 mg twice daily, increasing at 3-day intervals to 240 mg 
twice daily and then to 320 mg twice daily, unless reversion to 
sinus rhythm occurred or until side effects limited upward 
titration. At the end of the 9-day drug/placebo period, those 
patients remaining in atrial fibrillation underwent electrical 
cardioversion. It is from this group that the present study draws 
its subjects. 
To be eligible for the echocardiographic study, patients had 
to remain in sinus rhythm at least 2 h after electrical cardio- 
version and to have had a full two-dimensional echocardio- 
graphic and Doppler study performed within 2 to 24 h after 
cardioversion. Fifty-one subjects fulfilled these inclusion crite- 
ria. Patients were further excluded if they had any of the 
following features that would confound Doppler interpreta- 
tion: mitral stenosis (three patients), aortic stenosis (one 
patient), ejection fraction <35% (one patient), apaced rhythm 
at the time of echocardiographic study (two patients) or a 
technically suboptimal Doppler echocardiographic study un- 
suitable for accurate quantification (i.e., misplacement of 
sample volume, inappropriate v locity scale, high filter setting, 
[seven patients]). Thus, the remaining 37 patients form the 
basis of this report. Of these, 11 patients remained in sinus 
rhythm at 1 month and underwent a second Doppler echocar- 
diographic study to determine further changes in atrial func- 
tion. 
Echocardiographie measurements. All echocardiograms 
from the various participating centers were sent to the inves- 
tigators' site for analysis. Echocardiographic and Doppler 
measurements were performed off-line by one or both inves- 
tigators using a computerized digital analysis system (Cine- 
View Plus, Freeland Systems). M-mode measurements were 
obtained according to the American Society of Echocardiog- 
raphy guidelines (17). Left ventricular volumes were calculated 
by the biplane method of disks from the apical four- and 
two-chamber views (18) or by the single-plane method in 
patients who had suboptimal images in either the four- or 
two-chamber view. 
Pulsed Doppler of left ventricular inflow was performed in
the apical four-chamber view with the sample volume placed 
between the mitral leaflet ips and the ultrasound beam lined 
up in parallel to left ventricular inflow. The mitral velocity 
A B 
peak E peak E 
peak A 
DT DT 
Figure 1. Schematic representation f selected measurements per- 
formed on mitral Doppler inflow. Hatched areas represent the inte- 
grals of the E and A waves, respectively. A, At slower heart rate 
without overlap between E and A waves. B, At faster heart rate, with 
overlap. The E wave deceleration slope is extrapolated to the baseline, 
and the A wave integral excludes the area of overlap. A = A wave 
(atrial filling), DT = deceleration time, E = E wave (early diastolic 
filling). See Methods for details. 
tracings were digitized on-screen, following the contour of the 
Doppler spectral display on at least three consecutive beats to 
account for beat-to-beat variation. A schematic diagram of the 
measured mitral Doppler variables appears in Figure 1. Peak E 
and peak A wave velocities were measured. Acceleration time 
was measured from the start of mitral inflow to peak E wave. 
Deceleration time was measured from peak E wave to the time 
when the extrapolated descent of the E wave intercepted the 
zero baseline. Heart rate at the time of Doppler acquisition 
was calculated from the RR intervals of the analyzed wave- 
forms. Total diastolic mitral flow time-velocity integral as well 
as time-velocity integrals of the E and A waves were obtained 
according to previously published methodology (19-21). If 
there was overlap between E and A waves, the E wave integral 
was considered the area under the E wave extrapolated 
through the A wave to the baseline. The portion of the A wave 
integral incorporated in the E wave integral was not included 
in the A wave integral (20,21). If heart rate was slower and E 
and A waves did not overlap, the E wave integral was extrap- 
olated through diastasis to the baseline. The remaining small 
amount of flow during diastasis was not included in the integral 
of either E or A wave (19). Atrial filling fraction was defined as 
the A wave integral divided by the total diastolic time-velocity 
integral. 
Statistical analysis. Data are presented as mean value _+ 
SD. Considering the relatively small sample size, normal 
(Gaussian) distribution of data could not be assumed, and each 
variable was tested for normality by the Kolmogorov-Smirnov 
procedure (SigmaStat statistical analysis ystem, Jandel Scien- 
tific Co.). Comparisons between the two study groups used the 
two-sample t test for variables with normal distribution and 
equal variance and the Mann-Whitney rank-sum test for 
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Table l. Characteristics of Study Patients 
Placebo Sotalol 
(n = 20) (n = 17) p Value 
Age (yr) 64 _+ 9.5 61 _+ 8.6 NS 
Duration of atrial fibrillation (days) 133 ± 108 100 _+ 54 NS 
Left atrial size (M-mode) (cm) 4.8 + 0.9 5.2 + 0.6 NS 
Left ventricular ejection fraction (%) 57 ± 9 55 : 8 NS 
Significant mitral regurgitation 4/20 2/17 NS 
Data presented are mean value +_ SD or number of patients. 
variables with nonnormal distribution or unequal variance, or 
both. In comparing repeated measurements performed for the 
same patient (at 1 day and 1 month postcardioversion), the 
paired t test was used for variables with normal distribution, 
and the Wilcoxon signed-rank test was used for variables with 
non-normal distribution. Statistical significance was estab- 
lished at p < 0.05. 
Resu l ts  
Patient characteristics. Thirty-seven patients (mean age 63 
years, range 41 to 80) were included in the final analysis. The 
average duration of documented, sustained atrial fibrillation at 
time of randomization was 118 days. Seventeen patients had 
been randomized to receive sotalol and 20 to receive placebo. 
All but four patients were receiving 320 mg of sotalol twice 
daily at the time of electrical cardioversion. 
The main characteristics of the two study groups are 
detailed in Table 1. Mean age, duration of atrial fibrillation, 
left atrial size and left ventricular ejection fraction did not 
differ between groups. Two patients in the sotalol group and 
four in the placebo group had moderate to severe mitral 
regurgitation. Six patients in each group had trace or mild 
aortic incompetence. On the basis of exclusion criteria, none of 
the patients had mitral or aortic stenosis. 
Measurements of left ventricular inflow variables are pre- 
sented in Table 2. There was a significant difference in both the 
peak A wave velocity and A wave time-velocity integral 
between the two groups; each was approximately twice as large 
Table 2. Left Ventricular Inflow Doppler and Timing Variables 
Placebo Sotalol 
(n = 20) (n = 17) p Value 
Heart rate (beats/min) 70 ± 13 55 _+ 6 <0.001 
PR interval (ms) 182 z 24 180 _+ 29 NS 
Diastolic filling time (ms) 505 _+ 195 687 _- 108 <0.001 
Total time-velocity ntegral (cm) 18.9 _+ 8.1 18.0 _+ 5.0 NS 
Peak A wave velociW (cm/s) 38.4 +_ 14.7 19.4 ± 5.5 <0.001 
A wave time-velocity ntegral (cm) 3.4 _+ 1.4 1.7 + 0.6 <0.001 
Atrial filling fraction (%) 19.7 _+ 8.4 10.0 +_ 4.0 <0.001 
Peak E wave velocity (cm/s) 90,3 + 32.7 87.0 +_ 17.9 NS 
E wave time-velocity ntegral (cm) 14.0 +_ 6.2 14.2 _+ 4.8 NS 
E wave acceleration time (ms) 87 _+ 34 89 _+ 19 NS 
E wave deceleration time (ms) 187 _+ 45 217 ± 61 NS 
Data presented are mean value ± SD. 
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Figure 2. Individual and mean (_+SD) values of postcardioversion 
peak A wave velocity in placebo- (squares) and sotalol-treated (cir- 
cles) patients. Mean peak velocity in the sotalol group (0.19 + 
0.06 m/s) was significantly lower than that in the placebo group (0.38 -4- 
0.15 m/s, p < 0.001). 
in placebo-treated patients as that in sotalol-treated patients 
(Fig. 2). In contrast to A wave variables, the peak velocity and 
time-velocity integral of the E wave, as well as the total 
diastolic mitral time-velocity integral, were virtually identical 
in the two study groups. Consequently, the atrial contribution 
to ventricular filling in the sotalol group was about half that 
seen in the placebo group (sotalol group 10.0%, placebo group 
19.7%, p < 0.001). Mean heart rate was 15 beats/min slower in 
the sotalol group and resulted in a longer diastolic filling 
period in this group. This is attributed to the direct beta- 
blocking effect of the drug. The PR interval and acceleration 
and deceleration times were similar in both groups. 
Five sotalol-treated and six placebo-treated patients who 
continued with their therapy maintained sinus rhythm for at 
least 1 month after cardioversion. Mean heart rate was 67 
beats/min and 49 beats/min in the placebo and sotalol groups, 
respectively (p < 0.001). The individual changes in peak A 
wave velocity over this period are presented in Figure 3. All 
except wo of these patients had a higher peak A wave velocity 
at 1 month than immediately after electrical cardioversion. 
However, sotalol-treated patients had a considerably larger 
increase in peak A wave velocity (mean increase of 226%) than 
placebo-treated patients (mean increase of 48%, p < 0.05). 
Discuss ion  
In recent years, Doppler echocardiography as become a 
widely used technique for the study of left ventricular filling. 
Several investigators have noted that immediately after elec- 
trical cardioversion, the atrial contribution to ventricular filling 
is often small or even absent (22-26), an observation attributed 
to atrial "stunning" as a result of the prolonged arrhythmia 
(25,26). Serial measurements of Doppler echoeardiographic 
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Figure 3. Individual nd mean changes inpeak A wave velocity from 
the immediate postcardioversion D ppler study to that performed at1 
month in the 11 patients maintaining sinus rhythm. Squares represent 
patients receiving placebo, circles those receiving sotalol. Correspond- 
ing mean values are represented bythe appropriate dotted symbol. 
Sotalol-treated patients had a greater increase inmean peak A wave 
velocity than placebo-treated patients (226% vs. 48%, respectively p < 
0.05). 
indexes in those studies revealed a gradual recovery of atrial 
function over a period of several weeks (25,26) and provide 
support for the recommendation to continue anticoagulation 
for 2 to 3 weeks after return of sinus rhythm (27). 
A major problem with previous echocardiographic obser- 
vations is the inhomogeneity of the patients tudied. Previous 
studies did not stratify results by use of antiarrhythmic drugs, 
although the patients were receiving a variety of therapies, 
including class IA or IC drugs, beta-blockers or amiodarone. 
The wide range of therapy may confound the interpretation f 
postcardioversion Doppler echocardiography because these 
drugs may have effects on ventricular or atrial function, which 
could potentially alter transmitral Doppler flow patterns (28- 
30). 
To our knowledge, no previous tudy has specifically ad- 
dressed the characteristics of postcardioversion mitral Doppler 
flow pattern in the drug-flee state. In the present investigation 
the availability of a placebo group permitted us to examine 
this. We confirmed that, compared with published normal 
values of A wave velocities and time-velocity integrals (19,31), 
the mean postcardioversion A wave, in the absence of antiar- 
rhythmic drugs or beta-blockade, is considerably reduced. In 
addition, a more striking observation was that in subjects 
treated with sotalol, the postcardioversion mitral Doppler A 
wave was further educed compared with the already dimin- 
ished A wave seen in patients receiving placebo. This differ- 
ence in left ventricular filling pattern between the two groups 
was limited to the atrial wave, and no difference in early 
diastolic filling (E wave) was present. This indicates that sotalol 
has an isolated effect on late transmitral flow and suggests that 
the effects of sotalol must be taken into account before it is 
concluded that a small A wave represents an intrinsic abnor- 
mality of atrial function. 
Mechanism of effect of sotalol on mitral A wave. Doppler 
patterns of transmitral flow may be affected by multiple factors 
that directly or indirectly affect he heart. These include age 
(19,32-34), heart rate (19,20,34-36), PR interval (19,20), 
preload (37), intrinsic ventricular properties of relaxation and 
compliance (28) and (as is the case after cardioversion) 
impairment of atrial contraction. 
Assuming that impairment of atrial function is responsible 
for the small A wave noted in placebo-treated patients, what 
factors may account for the further reduction in the atrial 
contribution to ventricular filling seen in the sotalol-treated 
group? Randomization ensured a similar duration of arrhyth- 
mia in both groups, and the left atrial size did not differ 
between groups. The PR interval was the same. The age of 
patients in the two groups had a similar distribution, excluding 
age-related ifferences as a factor. Severe impairment of 
systolic function associated with high ventricular filling pres- 
sure may result in a "restrictive" filling pattern characterized 
by a shortened deceleration time and a small atrial component 
(38), but this was not the case here because patients with 
severe ventricular dysfunction were excluded from this study. 
Indeed, mean ejection fraction did not differ between sotalol- 
and placebo-treated patients and was in the low-normal range. 
Furthermore, the similarity of the E wave acceleration and 
deceleration times in sotalol- and placebo-treated patients 
implies that significant differences in relaxation and compli- 
ance of the left ventricle were not present and thus cannot be 
responsible for the differences noted in the A wave. 
One possible mechanism for the difference in the A wave is 
the difference inheart rate between the groups. Sotalol-treated 
patients had a slower heart rate than placebo-treated patients, 
and heart rate has been noted to affect A wave size, with 
tachycardia c using a shift of ventricular filling to late diastole, 
resulting in a greater atrial filling fraction (19,20,35,36). The 
magnitude of A wave changes associated with heart rate shifts 
is controversial. In a population-based study, Benjamin et al. 
(19) found a positive correlation between heart rate and both 
peak A wave velocity and atrial filling fraction. However, the 
correlation was weak, and the percent of the variance of peak 
A velocity attributable to heart rate was only 3%, with the 
majority of the variance attributable to age. Stewart et al. (36) 
recently used a multiple regression model to develop redic- 
tion formulas for mitral Doppler indexes based on age and 
heart rate in normal subjects. They found that for every 
increase in heart rate of 10 beats/rain, the expected mean 
change in peak A wave velocity is only 5.5%. This is far less 
than the observed oubling of A wave height in placebo- 
treated patients compared with sotalol-treated patients and 
suggests that although eart rate differences may have played 
a minor role, they cannot account for the observed magnitude 
of the difference in the A wave. 
Although the numbers are small, the argument that heart 
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rate does not play a major role in determining the differences 
in A waves is further supported by our observations on the 
1-month echocardiograms obtained in the sotalol- and place- 
bo-treated patients who remained in sinus rhythm (Fig. 3). 
Had bradycardia been a major factor in A wave reduction, the 
difference in A wave should have persisted at 1 month because 
the sotalol-induced bradycardia was still present. However, 
although both placebo- and sotalol-treated patients demon- 
strated the expected increase in A wave height (26,39,40), the 
mean percent increase in the sotalol-treated patients (226%) 
was significantly greater than that in placebo-treated patients 
(48%), resulting in virtual equalization ofthe A wave between 
the two groups. 
Having excluded all the recognized factors associated with a 
small A wave, we may reasonably conclude that the diminutive 
A wave found in the sotalol group primarily reflects a negative 
inotropic effect of the drug on atrial tissue. Although the 
predominant antiarrhythmic a tions of sotalol result from its 
class III properties, the drug is a racemic mixture of dextro and 
levo isomers, and the latter has significant beta-blocking 
effects. Precipitation of congestive heart failure during long- 
term drug therapy may occur and has been described in up to 
12.5% of patients, the majority of whom had preexisting 
systolic dysfunction (11). By analogy to systolic dysfunction, we 
postulate that a baseline atrial abnormality may be a pre- 
requisite for the manifestation f sotalol-induced atrial dys- 
function. After restoration of sinus rhythm, an increase in 
spontaneous echocardiographically visualized contrast has 
been noted in both the body of the left atrium and the atrial 
appendage (41). The left atrial appendage may transiently 
show even less contractility than in the precardioversion state. 
This phenomenon suggests a "stunning" of the atrium imme- 
diately after cardioversion. Such stunning may aggravate the 
propensity for a negative inotropic effect, as has been demon- 
strated in an animal model of postischemic myocardial dys- 
function (42). In this open chest animal model, dextro sotalol 
had only a slight effect on contractility of nonischemic myocar- 
dium compared with a more marked negative inotropic effect 
of either levo sotalol or of the racemic ompound, whereas in 
postischemic myocardium all these isomers, including dextro 
sotalol, produced a cardiodepressant effect (42). 
As shown in our placebo group, atrial function was mark- 
edly impaired after electrical cardioversion. We propose that, 
at this stage, the atrium is particularly vulnerable to potential 
negative inotropic properties of a drug such as sotalol and that 
the further diminution of A wave height in the sotalol group is 
a result of this phenomenon. Although we cannot draw firm 
conclusions regarding the duration of this atrial negative 
inotropic effect, the disproportionate improvement in A wave 
height in the small number of sotalol-treated patients restudied 
at 1 month (compared with the placebo-treated patients) 
suggests that it is a relatively short-lived phenomenon. 
We believe that the beta-blocking properties of the levo 
isomer of sotalol are the most likely cause of its negative 
inotropic effect on the atrium. However, as previously indi- 
cated, the dextro isomer may impair contractility in certain 
circumstances (42). Thus, at present, no specific property of 
racemic sotalol can be definitely stated to be responsible for 
this effect. Such data await further study. 
Limitations of the study. It might be argued that sotalol, by 
electrically stabilizing the atrium, favored sinus rhythm main- 
tenance in a greater proportion of patients with impaired atrial 
function, thereby biasing the sotalol group to include a greater 
number of those with small A waves. We believe this unlikely 
because there is little evidence to suggest that single Doppler 
measurements of atrial function correlate with stability of sinus 
rhythm (43,44). Furthermore, the number of patients in the 
sotalol and placebo groups was equal, as opposed to the 
expectation of a greater number of sotalol-treated patients if
maintenance of sinus rhythm was significantly better in subjects 
receiving active therapy. 
After cardioversion, the A wave height ends to increase 
from the immediate postcardioversion period to 24 h later 
(26,43). The echocardiograms in this study were all obtained 
within 24 h of cardioversion, but because of logistic difficulties 
at the various centers, they could not be standardized to be 
obtained at a more precise time. However, there is nothing to 
suggest abias in favor of earlier echocardiograms clustering in 
one group or another. 
Although the small number of 1-month echocardiograms 
suggested that the difference in sotalol- and placebo-treated 
patients became less apparent, the present study was primarily 
limited to the immediate postcardioversion period in which it 
has clearly demonstrated that a difference exists between 
placebo- and sotalol-treated patients. It is not known whether, 
if a larger group of patients had been studied at 1 month, some 
may have had a persistent drug-induced negative inotropic 
effect on the atrium. However, this does not affect he conclu- 
sions of the study, namely, that the excessive postcardioversion 
diminution of the A wave in sotalol-treated patients is a 
function of a negative inotropic effect on the stunned left 
atrium. 
Clinical implications. Attempts have been made to predict 
long-term maintenance of sinus rhythm from Doppler echo- 
cardiograms obtained shortly after cardioversion (43,44), but 
no reliable variables have been found. These studies did not 
consider possible ffects of antiarrhythmic drugs on the atrium, 
which, as the present study shows, may be profound. A number 
of other antiarrhythmic agents used for maintenance of sinus 
rhythm have negative inotropic effects on the ventricle, such as 
disopyramide, flecainide and propafenone. Because these 
agents have the potential to adversely affect he atrium, future 
attempts to predict recurrence of arrhythmia after cardiover- 
sion by examining variables of transmitral Doppler should take 
into account the use of specific agents. 
Delayed recovery of atrial function after cardioversion may 
be associated with a persistent risk of thromboembolic events 
until atrial function recovers (27), and it has been suggested 
that, in the immediate postinfarction period, beta-blockers 
may predispose to ventricular thrombus formation by virtue of 
a negative inotropic effect (45). Whether thromboembolic risk 
might be increased by atrial dysfunction precipitated by widely 
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used antiarrhythmic drugs is intriguing and warrants further 
consideration. Finally, recent data (39,40) suggest that im- 
provement of exercise tolerance after cardioversion is delayed, 
with its time course paralleling the return of atrial function. If 
it is shown that there is a persistent negative effect of sotalol 
and other agents on the atrium, then some of the potential 
benefit of cardioversion on functional capacity may be offset by 
this action. 
Conclusions. There is fertile ground for expanding the 
investigations of atrial function. However, until data are gen- 
erated from such studies, we believe it prudent, when evaluat- 
ing atrial function in an individual patient, to consider the 
potential effects of negative inotropic drugs on the atrium 
among the many variables that influence indexes of diastolic 
ventricular filling. 
We wish to thank Christopher P.Appleton, MD, for review and comments on the 
results of this study. The secretarial help of Janet Clare is also gratefully 
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